Novo Nordisk Inks Potential $255M Deal with EraCal, Targets Another Obesity Asset

While Novo Nordisk’s blockbuster obesity portfolio continues to rake in cash, the Danish pharma is looking to target a novel mechanism of action controlling appetite and body weight under a potential 235 million euros ($255 million) collaboration and license deal with Swiss biotech EraCal Therapeutics announced Tuesday.